PRISM Mid-Day Movers:
#AlzamendNeuro , Inc. ( #ALZN) soared 72%,
#nanovibronix , Inc. ( #NAOV) advanced 43%,
prismmarketview.com/prism-mid-da...

Alzamend Neuro Advances Alzheimer’s Drug Candidate into Phase II Trial Alzamend Neuro (ALZN) announced the initiation of a Phase II clinical trial for AL001, its lead drug candidate targeting mild to moderate Alzheimer’s disease.

#ALZN launches Phase II trial for AL001, a novel Alzheimer’s drug targeting disease modification and symptom relief. With FDA Fast Track status, it aims to address unmet needs for 6M+ patients.
#AlzamendNeuro #Alzheimers #Biotech #ClinicalTrials
Read more: prismmarketview.com/alzamend-neu...